Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 27, 2017

View Archived Issues

AG-348 well tolerated in updated data from phase II DRIVE PK study

WHSC1 revealed as a promising therapeutic target for ALL

Characterization of next-generation anti-CD19 half-life extended BiTE antibody

TP-0903 demonstrates promising in vitro and in vivo activity

NuCana BioMed patents adenosine derivatives for cancer

RedHill Biopharma begins phase IIa study of Yeliva in cholangiocarcinoma

FGFR inhibitors reported in Shanghai Allist Pharmaceutical patent

Enlibrium describes biguanide derivatives

Phase II study of anabasum in SLE begins

Arrowhead Pharmaceuticals seeks approval for phase I/II study of HBV drug

FDA issues complete response letter for Agile's Twirla

Mallinckrodt to acquire Sucampo Pharmaceuticals

FDA grants fast track designation for VAL-083 in recurrent glioblastoma

FDA updates Tasigna label to include information on stopping therapy in certain CML patients

Ono submits supplemental application for Opdivo in Japan

Poxel and Sumitomo Dainippon Pharma initiate phase III program for imeglimin

Arno Therapeutics sells remaining assets

Soliris approved in Japan for the treatment of patients with generalized myasthenia gravis

CG-806 receives orphan drug designation from FDA for treatment of AML

FDA grants fast track designation to cannabidiol oral solution for Prader-Willi syndrome

Agios submits NDA for ivosidenib to treat relapsed/refractory AML with an IDH1 mutation

Portola Pharmaceuticals provides update on BLA for AndexXa

Summit acquires Discuva and obtains innovative antibiotic discovery and development platform

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...